Skip to main content
Journal cover image

Epigenetic mechanisms underlying variation of IL-6, a well-established inflammation biomarker and risk factor for cardiovascular disease.

Publication ,  Journal Article
Lundin, JI; Peters, U; Hu, Y; Ammous, F; Benjamin, EJ; Bis, JC; Brody, JA; Cushman, M; Fuller, H; Gignoux, C; Guo, X; Haessler, J; Haiman, C ...
Published in: Atherosclerosis
August 2025

BACKGROUND AND AIMS: Cardiovascular disease (CVD) is one of the leading causes of morbidity and mortality worldwide, yet the underlying molecular mechanisms remain less understood. Chronic low-grade inflammation is a complex immune response contributing to the pathophysiology of cardiovascular disease. This response is signaled in part by interleukin-6 (IL-6), a pleiotropic, pro-inflammatory cytokine. Phenotypic variance in circulating IL-6 level may be explained in part by DNA methylation which is increasingly being associated with cardiovascular effects. METHODS: In this study we evaluated methylated DNA (CpG sites) associated with blood IL-6 levels across ∼4,400 ancestrally diverse individuals (81 % self-reported White; 9 % Black or African American, 8 % Hispanic or Latino/a, and 2 % Chinese American). RESULTS: We identified 178 CpG sites associated with IL-6 (p<0.05/∼395,000). Among the sites, cg04437762 is located within the transcription unit of IL6R, a current therapeutic target for inflammatory disease, and cg26692003 and cg00464927 were significant for IL6 and IL6ST trans-CpG-gene transcripts. Functional gene expression downstream of methylation identified cellular response to IL-6 and B-cell regulation and activation pathways. Four genes were linked with both a genetic component of cardiovascular disease and an IL-6 associated CpG site. Three CpG sites identified through Mendelian randomization analyses supported inference of a causal effect on IL-6 levels, including the LYN gene that regulates immune cell signaling and has been previously associated with atherosclerosis. CONCLUSIONS: Overall, we identified several novel IL-6-CpG sites and downstream pathways affected by methylation. Follow-up functional studies including the regulation of IL-6 would complement current knowledge of CVD pathophysiology and potential therapeutic targets.

Duke Scholars

Published In

Atherosclerosis

DOI

EISSN

1879-1484

Publication Date

August 2025

Volume

407

Start / End Page

120219

Location

Ireland

Related Subject Headings

  • Risk Factors
  • Receptors, Interleukin-6
  • Middle Aged
  • Male
  • Interleukin-6
  • Inflammation
  • Humans
  • Heart Disease Risk Factors
  • Genetic Predisposition to Disease
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lundin, J. I., Peters, U., Hu, Y., Ammous, F., Benjamin, E. J., Bis, J. C., … PAGE Study. (2025). Epigenetic mechanisms underlying variation of IL-6, a well-established inflammation biomarker and risk factor for cardiovascular disease. Atherosclerosis, 407, 120219. https://doi.org/10.1016/j.atherosclerosis.2025.120219
Lundin, Jessica I., Ulrike Peters, Yao Hu, Farah Ammous, Emelia J. Benjamin, Joshua C. Bis, Jennifer A. Brody, et al. “Epigenetic mechanisms underlying variation of IL-6, a well-established inflammation biomarker and risk factor for cardiovascular disease.Atherosclerosis 407 (August 2025): 120219. https://doi.org/10.1016/j.atherosclerosis.2025.120219.
Lundin JI, Peters U, Hu Y, Ammous F, Benjamin EJ, Bis JC, et al. Epigenetic mechanisms underlying variation of IL-6, a well-established inflammation biomarker and risk factor for cardiovascular disease. Atherosclerosis. 2025 Aug;407:120219.
Lundin, Jessica I., et al. “Epigenetic mechanisms underlying variation of IL-6, a well-established inflammation biomarker and risk factor for cardiovascular disease.Atherosclerosis, vol. 407, Aug. 2025, p. 120219. Pubmed, doi:10.1016/j.atherosclerosis.2025.120219.
Lundin JI, Peters U, Hu Y, Ammous F, Benjamin EJ, Bis JC, Brody JA, Cushman M, Fuller H, Gignoux C, Guo X, Haessler J, Haiman C, Joehanes R, Kasela S, Kenny E, Lappalainen T, Levy D, Liu C, Liu Y, Loos RJF, Matise T, North KE, Park SL, Ratliff SM, Reiner A, Rich SS, Rotter JI, Smith JA, Sotoodehnia N, Tracy R, Van den Berg D, Ye T, Zhao W, Raffield LM, Kooperberg C, PAGE Study. Epigenetic mechanisms underlying variation of IL-6, a well-established inflammation biomarker and risk factor for cardiovascular disease. Atherosclerosis. 2025 Aug;407:120219.
Journal cover image

Published In

Atherosclerosis

DOI

EISSN

1879-1484

Publication Date

August 2025

Volume

407

Start / End Page

120219

Location

Ireland

Related Subject Headings

  • Risk Factors
  • Receptors, Interleukin-6
  • Middle Aged
  • Male
  • Interleukin-6
  • Inflammation
  • Humans
  • Heart Disease Risk Factors
  • Genetic Predisposition to Disease
  • Female